Abstract:

Objective To evaluate the efficacy of ⁸⁹SrCl₂ combined with 99Tc-MDP for patients with bone metastases. Methods Randomized controlled trials published up to June 2015 that compared ⁸⁹SrCl₂  combined with ⁹⁹Tc-MDP and ⁸⁹SrCl₂  alone for treating patients with bone metastases were retrieved from databases including the Cochrane Library，PubMed，EMBASE，WanFang，CBM，CNKI，and VIP. The quality of eligible studies was evaluated，and data were meta-analyzed using Revman 5.3. Results A total of 7 RCTs involving 691 patients were included in the meta-analysis. The combination of ⁸⁹SrCl₂  and ⁹⁹Tc-MDP led to significantly higher efficacy in bone pain palliation（RR=0.16，95%CI：0.10-0.22），higher radionuclide bone scan score （RR= 1.31，95%CI：1.07-1.60） and higher KPS score（RR=1.68， 95%CI：1.33-2.12）. The most frequent adverse reactions were leukopenia and thrombocytopenia. Conclusions The available evidence suggests that the combination of ⁸⁹SrCl₂  and ⁹⁹Tc-MDP is superior to ⁸⁹SrCl₂ alone for palliating bone pain and improving radionuclide bone scan and KPS scores in patients with bone metastases. However，these findings should be confirmed and extended in future studies.

Key words: Bone metastasis, Radionuclide therapy, ⁸⁹SrCl₂, ⁹⁹Tc-MDP, Meta-analysis